

Understanding and managing acute respiratory distress syndrome (ARDS): New pharmacological approaches reviewing recent developments in the pharmacological management of ARDS

Akash Jain

Department of Pharmacology, M.M.
College of Pharmacy, Ambala, Haryana,
India

Correspondence:

Dr. Akash Jain, Department of
Pharmacology, M.M. College of Pharmacy,
Ambala, Haryana, India.
E-mail: akash.jain@mmumullana.org

How to cite this article:

Jain A.
Understanding and managing acute
respiratory distress syndrome
(ARDS): New pharmacological
approaches reviewing recent
developments in the pharmacological
management of ARDS. Innov Pharm
Planet (IP-Planet) 2024;12(1):5-9.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 09-02-2024

Date of Revision: 17-02-2024

Date of Acceptance: 20-02-2024

ABSTRACT

Acute respiratory distress syndrome (ARDS) remains a major cause of morbidity and mortality in critical care, characterized by severe inflammation, endothelial damage, and impaired gas exchange. This review explores the current and future pharmacological approaches to ARDS management. Present standard care includes mechanical ventilation strategies, adjunctive therapies such as extracorporeal membrane oxygenation and prone positioning, and pharmacological interventions such as corticosteroids and neuromuscular blockers. However, treatment challenges, including the heterogeneity of ARDS and adverse effects of current therapies, have driven the need for new approaches. Emerging pharmacological options, including biologics, endothelial stabilizers, and mesenchymal stem cell therapies, aim to target the underlying pathophysiology more precisely. Advances in pharmacogenomics and personalized medicine promise to optimize treatment by identifying genetic susceptibilities and using biomarker-guided therapies. Ongoing clinical trials and exploration of gene therapies offer additional hope for modifying ARDS at a molecular level. In addition, AI and big data are being integrated to enhance precision medicine and optimize patient outcomes. These innovations represent a paradigm shift in ARDS management, offering more tailored, effective treatments that could significantly reduce mortality and improve long-term outcomes.

Keywords: Acute respiratory distress syndrome, biologics, mesenchymal stem cell therapy, personalized medicine, pharmacological management

Introduction

Acute respiratory distress syndrome (ARDS) is a severe, rapidly progressing condition characterized by acute inflammation and increased permeability of the alveolar-capillary membrane, leading to fluid accumulation in the alveoli and impaired gas exchange. It holds significant relevance in critical care medicine due to its high morbidity and mortality rates, with approximately 10–15% of intensive care unit (ICU) patients affected and an overall mortality rate ranging from 30% to 40%. The pathophysiology involves a cascade

of inflammatory responses, endothelial damage, and compromised pulmonary function, which together result in severe hypoxemia and respiratory failure.^[1]

The clinical impact of ARDS is profound, placing a substantial burden on healthcare systems through prolonged ICU stays, mechanical ventilation, and high healthcare costs, as well as causing significant long-term health impairments and diminished quality of life in survivors. Despite advancements in supportive care, including mechanical ventilation and corticosteroids, the high mortality rate and limitations of current therapies underscore the urgent need for new pharmacological approaches. Novel treatments targeting the underlying inflammatory and cellular mechanisms of ARDS, as well as personalized medicine strategies, are essential for improving patient outcomes and reducing the overall burden of this challenging syndrome.^[2]

Access this article online

Website: <https://innovationaljournals.com/index.php/ip> **e-ISSN:** 2348-7275

DOI: 10.31690/ipplanet.2024.v012i01.002

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Current Standard of Care in ARDS Management

Ventilation, adjunctive therapies, and pharmacological treatments

Current standard care for ARDS focuses primarily on supportive measures, with mechanical ventilation strategies being central to treatment. The current best practices in mechanical ventilation for ARDS include the use of low tidal volume ventilation, which aims to minimize ventilator-induced lung injury by reducing the volume of air delivered to the lungs with each breath. Typically, tidal volumes are set at 6 mL/kg of predicted body weight, as opposed to the traditional 10–12 mL/kg, which has been shown to improve outcomes and reduce mortality. In addition, positive end-expiratory pressure (PEEP) is utilized to prevent alveolar collapse and improve oxygenation by maintaining lung volume and reducing shunting. The application of PEEP, adjusted according to individual patient needs, helps in recruiting collapsed lung units and improving overall ventilation-perfusion matching.^[3]

In addition to mechanical ventilation, several adjunctive therapies are employed to manage ARDS. Extracorporeal membrane oxygenation (ECMO) is a technique that provides respiratory and cardiac support by oxygenating blood outside the body, thereby reducing the need for mechanical ventilation and improving oxygenation. Prone positioning, where patients are placed in a face-down position, has been shown to enhance ventilation and oxygenation in ARDS patients by improving the distribution of lung perfusion and reducing ventral lung compression. Fluid management is also critical, with strategies focusing on maintaining fluid balance and avoiding excessive fluid resuscitation, which can exacerbate pulmonary edema. These adjunctive therapies, along with careful monitoring and individualized adjustments, play a crucial role in managing ARDS and optimizing patient outcomes.^[4]

Pharmacological treatments conventionally used in ARDS management include corticosteroids, neuromuscular blockers, and various supportive therapies. Corticosteroids, such as dexamethasone, have become a cornerstone in ARDS treatment due to their anti-inflammatory effects, which help reduce lung inflammation and improve survival rates. Neuromuscular blockers, like cisatracurium, are used in patients with severe ARDS to facilitate better ventilation by reducing respiratory muscle workload and improving synchrony with the ventilator. Supportive therapies, including sedation and antibiotics, are also crucial in managing ARDS. Sedatives help control agitation and ensure adequate ventilation, while antibiotics are administered to treat or prevent secondary infections that can complicate ARDS. Despite the benefits of these treatments, their use must be carefully balanced to avoid potential side effects and complications, and ongoing research continues to refine their optimal application.^[5]

Challenges in ARDS Treatment

The treatment of ARDS is fraught with several significant challenges, primarily due to the heterogeneity of the condition and the limitations

of current therapeutic strategies. One of the major difficulties in managing ARDS stems from its variability among patients. ARDS is a complex syndrome with diverse etiologies and clinical presentations, leading to different responses to treatments. This heterogeneity complicates the application of uniform treatment protocols and highlights the need for personalized approaches. Patients with ARDS can exhibit varying degrees of inflammation, lung injury, and underlying comorbidities, which can influence their response to mechanical ventilation, pharmacological agents, and adjunctive therapies. This variability makes it challenging to predict outcomes and tailor treatments effectively for each individual, often leading to suboptimal management and variability in clinical outcomes.^[6]

Another significant challenge in ARDS treatment is the lack of targeted therapies. The pathophysiology of ARDS involves a complex interplay of inflammatory and cellular mechanisms, and identifying specific pharmacological targets has proven difficult. Current therapies primarily focus on supportive care and non-specific anti-inflammatory agents, but these treatments do not directly address the underlying molecular and cellular abnormalities of ARDS. For instance, while corticosteroids have been shown to improve survival, they do not selectively target the inflammatory pathways most critical to ARDS pathology. The absence of more targeted therapies reflects the need for a deeper understanding of the disease mechanisms and the development of drugs that can more precisely modulate the inflammatory response and improve outcomes.

In addition, the adverse effects of current treatments pose significant limitations. Mechanical ventilation, while essential for supporting breathing, can contribute to ventilator-induced lung injury and barotrauma if not carefully managed. High levels of PEEP and mechanical ventilation settings may exacerbate lung injury in some cases. Corticosteroids, despite their efficacy, can lead to a range of side effects, including increased susceptibility to infections, hyperglycemia, and gastrointestinal bleeding. Neuromuscular blockers, although beneficial for reducing ventilator workload, carry risks of muscle weakness and prolonged neuromuscular impairment. These adverse effects underscore the need for careful balancing of benefits and risks in ARDS treatment and highlight the importance of ongoing research to develop safer and more effective therapeutic options.^[7]

New pharmacological approaches in ARDS management

Recent advancements in the management of ARDS have led to the development of several promising pharmacological approaches aimed at improving treatment outcomes. One significant area of focus is anti-inflammatory agents. Corticosteroids,^[8] a mainstay in ARDS treatment, are now being evaluated with new insights into optimal dosing and timing. Studies suggest that early administration of moderate doses may be more effective compared to late or high-dose regimens, potentially improving patient outcomes while minimizing side effects. Biologic agents have also gained attention for their ability to target specific inflammatory pathways. For instance, Interleukin-6 (IL-6) inhibitors like tocilizumab, tumor necrosis factor-alpha (TNF- α) inhibitors, and anti-IL-1 therapies are being explored for

their potential to reduce inflammation and mitigate ARDS severity. In addition, sphingosine-1-phosphate (S1P) receptor modulators, which target novel anti-inflammatory pathways, have shown promise in preclinical models for their ability to reduce inflammation and improve lung function.

Antiviral and antimicrobial agents represent another important development in ARDS treatment, particularly in the context of viral infections such as COVID-19. Targeted antivirals, which aim to inhibit viral replication and reduce viral load, are being investigated for their potential to slow ARDS progression. Prophylactic antimicrobials are also being evaluated to prevent secondary bacterial infections, which are common in ARDS patients and can exacerbate lung injury and inflammation. Endothelial stabilizers offer a novel approach by focusing on the vascular aspects of ARDS. The Angiopoietin/Tie2 signaling pathway, crucial for maintaining endothelial cell integrity and regulating vascular permeability, is a target for reducing vascular leakage and inflammation. New vasodilators are also being studied for their potential to enhance pulmonary blood flow and improve oxygenation.

Mesenchymal stem cell (MSC) therapies present another innovative strategy, with their immunomodulatory effects potentially reducing inflammation and promoting tissue repair in ARDS. Ongoing clinical trials are exploring their efficacy, with early results indicating benefits in reducing inflammation and improving lung function. In addition, novel inhalation therapies are being researched, including nitric oxide and other gaseous therapies that improve oxygenation and have anti-inflammatory effects through selective vasodilation of pulmonary vessels. Aerosolized surfactants are also under investigation for their ability to reduce alveolar collapse and restore normal surfactant levels, potentially improving lung function. These emerging pharmacological approaches highlight the progress being made in ARDS treatment and the potential for more effective and targeted therapies in the future.^[9]

Pharmacogenomics and Personalized Medicine in ARDS

Tailoring treatment for better outcomes

The integration of pharmacogenomics and personalized medicine into the treatment of ARDS has the potential to revolutionize how this complex and heterogeneous condition is managed. ARDS is characterized by wide variability in patient responses to treatment, which is increasingly recognized as being influenced by underlying genetic factors. Genetic susceptibility to ARDS refers to how genetic variability affects an individual's risk of developing the syndrome, as well as the severity and outcome of the disease. For example, certain genetic polymorphisms in genes involved in inflammation, immune responses, and epithelial and endothelial function can influence the degree of lung injury and recovery.^[10] Variants in cytokine-related genes, such as those encoding IL-6 and TNF- α , can lead to either heightened or dampened inflammatory responses, directly affecting the clinical course of ARDS. Similarly, polymorphisms in genes regulating the production of surfactant proteins, essential for maintaining alveolar stability, can influence the effectiveness of lung-protective strategies like mechanical ventilation or surfactant

replacement therapies. These insights into genetic variability are critical for identifying patients at higher risk for severe ARDS and tailoring treatments accordingly.^[11]

Pharmacogenomic studies have identified several genetic markers associated with varying responses to conventional ARDS therapies, such as corticosteroids and neuromuscular blockers. For instance, certain polymorphisms in the glucocorticoid receptor gene may determine the efficacy of corticosteroids, which are commonly used to dampen excessive inflammation in ARDS. These genetic differences can explain why some patients benefit from steroid therapy while others experience limited improvement or adverse effects. Understanding these genetic factors allows clinicians to better predict who might benefit from specific therapies and avoid unnecessary treatment for those less likely to respond.^[12] Similarly, genes involved in the metabolism and transport of pharmacological agents, such as those affecting cytochrome P450 enzymes, can influence drug efficacy and toxicity. As pharmacogenomic research advances, identifying these genetic variants will become an essential step in optimizing the therapeutic regimen for each ARDS patient.

Biomarker-guided therapies are another promising aspect of personalized medicine in ARDS, allowing for real-time adjustments to treatment based on measurable biological markers. Biomarkers like C-reactive protein, procalcitonin, and IL-6 can help stratify patients based on their inflammatory burden, allowing clinicians to tailor anti-inflammatory treatments like corticosteroids, biologics, or immune-modulating agents to those who are most likely to benefit. Emerging biomarkers, such as endothelial dysfunction markers like angiopoietin-2 and von Willebrand factor, offer insights into vascular permeability and injury, which are central to the pathophysiology of ARDS. These markers can guide the use of therapies aimed at stabilizing the endothelium, such as Tie2 agonists or vascular-targeted agents, potentially improving outcomes for patients with severe endothelial damage. In addition, integrating biomarkers of oxidative stress, alveolar injury (e.g., surfactant protein D), and immune dysregulation can refine treatment algorithms and help in selecting the most appropriate therapeutic strategies for individual patients.

Furthermore, personalized medicine in ARDS goes beyond just genetic and biomarker profiling; it involves integrating a range of patient-specific data to tailor treatments precisely. This includes factors such as the etiology of ARDS (e.g., sepsis-induced, viral infection-related), the timing of therapeutic interventions, and patient-specific characteristics such as age, comorbidities, and underlying organ function. For example, patients with ARDS caused by viral infections like COVID-19 may have distinct inflammatory and immune profiles compared to those with bacterial sepsis-induced ARDS, necessitating different approaches. The COVID-19 pandemic has also accelerated the development of antiviral therapies and immune-modulating agents, offering a template for precision treatment of ARDS. Targeted antivirals, such as remdesivir, and immune-modulating biologics, such as IL-6 inhibitors like tocilizumab, are already being incorporated into treatment regimens based on specific viral loads and inflammatory profiles. These advances demonstrate the growing importance of personalizing therapies to improve outcomes in ARDS.^[13]

Moreover, as clinical trials continue to explore the utility of novel pharmacological agents, integrating pharmacogenomic data with machine learning algorithms may further enhance our ability to predict which treatments will be most effective for a given patient. This approach would allow for dynamic, data-driven decision-making in ARDS management, facilitating more accurate prognosis and optimized therapy. The eventual goal is to develop precision medicine algorithms that incorporate genetic information, biomarker levels, and clinical data into real-time therapeutic decisions, ensuring that each ARDS patient receives the most appropriate and effective treatments.

Future Directions in ARDS Treatment

Harnessing innovation for enhanced outcomes

The future of ARDS treatment is rapidly evolving, with a multitude of novel therapeutic strategies and technological innovations that promise to improve both short- and long-term outcomes. One key focus is on the potential for combination therapies, which aim to exploit synergistic effects by integrating pharmacological agents with established supportive care, such as mechanical ventilation. Studies suggest that anti-inflammatory agents, such as biologics targeting IL-6 or TNF- α , can be more effective when combined with strategies like low tidal volume ventilation. This approach could further reduce ventilator-induced lung injury by attenuating the inflammatory response while maintaining lung-protective ventilation. In addition, the use of prone positioning, which improves oxygenation in severe ARDS, is being explored in conjunction with endothelial stabilizing agents such as Tie2 agonists or S1P receptor modulators. This combinatory approach may stabilize vascular integrity, decrease pulmonary edema, and reduce oxygen dependency, leading to better outcomes for patients with diverse ARDS etiologies. Researchers are also examining the pairing of immune-modulating drugs with ECMO to enhance oxygenation while reducing systemic inflammation in critically ill patients.^[7]

Ongoing clinical trials are at the forefront of ARDS research, testing new pharmacological agents that target the underlying mechanisms of the disease. These trials aim to develop drugs that go beyond supportive care to modify the disease's trajectory. Among the most promising are biological therapies that inhibit key inflammatory mediators, such as IL-1, IL-8, and CCL2, all of which are implicated in the cytokine storm that drives ARDS pathology. In addition, phase 2 and 3 trials are investigating novel anti-fibrotic agents, which could be particularly useful for preventing the progression of fibrosis in patients who survive the acute phase of ARDS but are at risk of developing long-term lung damage. Similarly, drugs targeting the Angiopoietin-Tie2 pathway, which regulates endothelial permeability and vascular integrity, are being evaluated for their ability to prevent fluid leakage into the lungs and reduce vascular inflammation. Another area of clinical interest is the use of MSC therapies, which have shown immunomodulatory and regenerative potential. Recent trials suggest that MSCs may reduce inflammation and promote tissue repair in ARDS patients, offering hope for a novel therapy that addresses both lung injury and the immune dysregulation characteristic of the syndrome. As these trials progress, they are expected to provide critical insights into the next generation of ARDS treatments.

An even more cutting-edge frontier in ARDS treatment involves the potential use of gene therapies, which target the condition at its genetic and molecular roots. While still largely in the experimental phase, gene therapy holds the promise of modifying the immune response, reducing the risk of excessive inflammation, and enhancing the lung's natural repair mechanisms. For instance, gene therapy approaches could be used to increase the production of surfactant proteins, which are crucial for maintaining alveolar stability and preventing collapse during ARDS. By targeting specific pathways involved in lung injury, gene therapies could provide a way to directly alter the disease course in individuals predisposed to severe ARDS due to genetic factors. Emerging techniques like CRISPR-Cas9, which enable precise editing of the genome, offer the possibility of correcting genetic mutations that contribute to abnormal immune or endothelial responses, potentially preventing the onset or progression of ARDS. In addition, epigenetic therapies, which modify the regulation of gene expression without altering the underlying DNA sequence, are being explored as a way to reset the inflammatory response or promote lung healing. While these therapies are still in the preclinical phase, their potential impact on ARDS treatment is substantial, providing a glimpse into a future where genetic interventions could fundamentally alter the management of critical lung conditions.

Another transformative approach in ARDS treatment is the integration of artificial intelligence (AI) and big data analytics into clinical practice. AI has the potential to revolutionize how ARDS is managed by enabling precision medicine on an unprecedented scale. Machine learning algorithms, which can process vast amounts of clinical data, genetic information, and biomarker profiles, are already being developed to predict which patients are most likely to respond to specific therapies. These models can analyze complex datasets in real time, providing personalized treatment recommendations that consider each patient's unique genetic makeup, inflammatory markers, and clinical course. AI can also optimize mechanical ventilation by continuously monitoring patient responses and adjusting ventilation settings to reduce lung injury while maximizing oxygenation. Furthermore, AI-driven predictive models are being developed to identify patients at the highest risk for developing ARDS, allowing for earlier interventions and potentially reducing the incidence of severe cases. Big data analytics, combined with AI, could also facilitate the identification of new biomarkers and therapeutic targets, accelerating drug discovery and the development of more effective treatments.^[14]

In addition to AI, big data analytics offers immense potential for improving the management of ARDS. The aggregation of data from thousands of ARDS cases worldwide, including genetic, clinical, and treatment response information, allows researchers to identify patterns and correlations that may not be evident through traditional research methods. This global data network could help uncover new risk factors, refine treatment algorithms, and reveal novel drug targets. The use of cloud-based platforms for data sharing across institutions also accelerates the pace of research and enables collaboration on a global scale. For instance, data-driven insights from the COVID-19 pandemic have already contributed to the identification of key inflammatory pathways involved in ARDS and led to the rapid development of targeted therapies. As more data becomes available,

it will enable clinicians to make better-informed decisions, ultimately improving patient outcomes by offering highly personalized care tailored to each individual's biological profile.

Conclusion

The management of ARDS is evolving through a combination of innovative pharmacological approaches, advanced mechanical ventilation strategies, and the integration of personalized medicine. Emerging therapies, including biologics, stem cell treatments, and endothelial stabilizers, hold promise in targeting both inflammatory and vascular mechanisms of ARDS. The advent of pharmacogenomics, gene therapies, and AI-driven precision medicine further enhances the potential for tailored treatments, reducing mortality and improving patient outcomes. As ongoing clinical trials and technological innovations continue to shape ARDS care, future therapies are expected to offer more effective, individualized solutions for this complex syndrome.

References

1. Bos LD, Laffey JG, Ware LB, Heijnen NF, Sinha P, Patel B, *et al.* Towards a biological definition of ARDS: Are treatable traits the solution? *Intensive Care Med* 2022;10:8.
2. Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and Covid-19 lung injury. *Crit Care Clin* 2021;37:749-76.
3. Kassis EB, Loring SH, Talmor D. Mortality and pulmonary mechanics in relation to respiratory system and transpulmonary driving pressures in ARDS. *Intensive Care Med* 2016;42:1206-13.
4. Aokage T, Palmér K, Ichiba S, Takeda S. Extracorporeal membrane oxygenation for acute respiratory distress syndrome. *J Intensive Care* 2015;3:17.
5. Alhazzani W, Belley-Cote E, Möller MH, Angus DC, Papazian L, Arabi YM, *et al.* Neuromuscular blockade in patients with ARDS: A rapid practice guideline. *Intensive Care Med* 2020;46:1977-86.
6. Wick KD, McAuley DF, Levitt JE, Beitler JR, Annane D, Riviello ED, Promises and challenges of personalized medicine to guide ARDS therapy. *Crit Care* 2021;25:404.
7. Qadir N, Chang SY. Pharmacologic treatments for acute respiratory distress syndrome. *Crit Care Clin* 2021;37:877-93.
8. Khilani GC, Hadda V. Corticosteroids and ARDS: A review of treatment and prevention evidence. *Lung India* 2011;28:114-9.
9. Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: Current clinical progress in ARDS and COVID-19. *Stem Cell Res Ther* 2020;11:305.
10. Villar J, Flores C. Assessing the quality of studies supporting genetic susceptibility and outcomes of ARDS. *Front Genet* 2014;5:73505.
11. García-Laorden M, Rodríguez de Castro F, Solé-Violán J, Rajas O, Blanquer J, Borderías L, *et al.* Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: A prospective, observational, genetic study. *Crit Care* 2011;15:R57.
12. Liu J, Dean DA. Gene therapy for acute respiratory distress syndrome. *Front Physiol* 2022;12:786255.
13. Ge R, Wang F, Peng Z. Advances in biomarkers for diagnosis and treatment of ARDS. *Diagnostics (Basel, Switzerland)* 2023;13:3296.
14. Pai KC, Chao WC, Huang YL, Sheu RK, Chen LC, Wang MS, *et al.* Artificial intelligence-aided diagnosis model for acute respiratory distress syndrome combining clinical data and chest radiographs. *Digit Health* 2022;8:1-15.